counterregulatori
ra
made
variou
peptid
receptor
enzym
fig
wherea
effect
angiotensin
angiotensin
cardiovascular
system
explor
potenti
role
counterregulatori
ra
compon
remain
poorli
understood
noncanon
ra
compon
includ
alamandin
angiotensin
angiotensin
well
angiotensin
angiotensin
also
known
angiotensin
iii
iv
figur
show
molecular
structur
peptid
past
year
new
evid
emerg
signal
pathway
trigger
counterregulatori
ra
reveal
role
potenti
therapeut
target
cardiovascular
diseas
cvd
angiotensin
act
agonist
type
angiotensin
ii
receptor
without
activ
gq
subunit
mechan
might
contribut
antihypertroph
properti
angiotensin
given
neither
activ
protooncogen
ma
receptor
antagonist
prevent
benefici
effect
alamandin
activ
ampactiv
protein
kinas
ampk
oxid
pathway
via
masrel
g
proteincoupl
receptor
member
mrgd
prevent
angiotensin
iiinduc
contrast
angiotensin
stimul
signal
pathway
protect
myocardium
reperfusioninduc
cell
moreov
angiotensin
shown
regul
intracellular
calcium
transient
left
ventricular
contractil
function
normal
rat
rat
heart
failur
hf
via
chymasedepend
cyclic
ampdepend
addit
angiotensin
found
induc
atrial
natriuret
peptid
anp
secret
isol
perfus
rat
atria
bind
ma
receptor
activ
phosphatidylinositol
synthas
lastli
angiotensinogen
precursor
entir
ra
famili
peptid
date
studi
shown
angiotensinogen
elicit
direct
biolog
effect
heart
nonetheless
aryl
hydrocarbon
receptor
nuclear
translocatorlik
protein
shown
modul
blood
pressur
mechan
involv
transcript
regul
angiotensinogen
circadian
manner
perivascular
adipos
tissu
turn
increas
local
angiotensin
ii
novel
find
shed
light
complex
regul
classic
ra
suggest
similar
complex
counterregulatori
system
context
circadian
express
local
angiotensinogen
might
affect
organspecif
activ
peptid
known
cardiovascular
effect
angiotensin
angiotensin
requir
investig
noncanon
ra
angiotensin
angiotensin
bind
ma
receptor
respect
wherea
alamandin
act
fig
angiotensin
also
bind
mrgd
function
relev
associ
remain
emerg
evid
reveal
complex
interact
compon
classic
counterregulatori
ra
initi
thought
given
angiotensin
also
shown
bind
moreov
form
heterodim
ma
receptor
inhibit
activ
use
radiolabel
dynam
mass
redistribut
experi
cell
overexpress
ma
receptor
gaidarov
colleagu
found
although
angiotensin
antagon
angiotensin
ii
signal
angiotensin
bind
directli
ma
data
conflict
earlier
studi
demonstr
bind
fluoresc
angiotensin
ma
gaidarov
colleagu
note
absenc
ma
receptor
angiotensin
effect
angiotensin
ii
howev
investig
also
reiter
rigor
control
experi
demonstr
interact
angiotensin
ma
receptor
scarc
moreov
given
find
suggest
angiotensin
bind
ma
receptor
research
hypothes
cardioprotect
effect
angiotensin
might
attribut
antagon
angiotensin
ii
nevertheless
addit
studi
requir
confirm
whether
angiotensin
endogen
agonist
ma
receptor
meem
colleagu
design
synthes
peptid
simultan
activ
ma
receptor
particul
guanylyl
cyclas
gener
fusion
angiotensin
acid
sequenc
btype
natriuret
peptid
bnp
reduc
blood
pressur
cardiac
unload
system
vascular
resist
exert
potent
natriuret
diuret
effect
separ
administr
bnp
angiotensin
observ
rais
possibl
fusion
counterregulatori
ra
ligand
target
one
receptor
might
also
induc
synergist
effect
mediat
potent
cardioprotect
benefit
form
function
heterodim
ma
receptor
highlight
possibl
develop
drug
select
target
monom
oligom
upregul
downregul
specif
cell
signal
cascad
cardiovascular
addit
crystal
structur
human
bound
select
ligand
indic
ligand
induc
activ
conform
receptor
suggest
bind
g
protein
tetzner
colleagu
show
angiotensin
bind
mrgd
antagonist
block
ma
receptor
latter
find
particularli
import
given
larg
number
studi
util
assess
effect
activ
figur
provid
overview
signal
pathway
trigger
counterregulatori
ra
ligand
upon
bind
receptor
ace
inhibitor
firstlin
pharmacolog
therapi
manag
hypertens
proteas
neprilysin
also
known
neutral
endopeptidas
identifi
novel
therapeut
target
given
enzym
also
reduc
blood
pressur
might
reduc
blood
pressur
level
gener
angiotensin
angiotensin
ii
wherea
inhibit
neprilysin
increas
anp
addit
endogen
metabol
regul
fibroblast
growth
factor
promot
gener
adipocyt
renal
cell
therebi
promot
cleavag
angiotensin
ii
form
angiotensin
suggest
reduc
angiotensin
iiinduc
classic
ra
act
local
system
level
signal
coordin
poorli
understood
exosom
extracellular
vesicl
nm
size
transport
transmit
molecul
protein
microrna
one
cell
anoth
also
transport
compon
classic
previous
assum
scatter
cellular
wast
exosom
attract
much
research
interest
sinc
discoveri
role
intercellular
consid
extracellular
vesicl
commun
signal
afar
counterregulatori
ra
exert
effect
multipl
cell
type
vesicl
might
role
orchestr
effect
counterregulatori
ra
context
pironti
colleagu
observ
exosom
induc
cardiac
pressur
overload
mice
contain
function
might
influenc
regul
vascular
moreov
exosom
seem
role
local
ra
angiotensin
ii
trigger
exosom
product
rat
cardiac
fibroblast
vitro
exosom
turn
promot
angiotensin
ii
product
express
rat
cardiomyocyt
vitro
suggest
posit
feedback
mechan
might
contribut
exacerb
cardiac
hypertrophi
elicit
angiotensin
howev
evid
support
role
exosom
orchestr
effect
canon
ra
whether
extracellular
vesicl
contribut
cardioprotect
properti
counterregulatori
ra
remain
determin
first
describ
receptor
sever
acut
respiratori
syndrom
coronaviru
character
mark
homolog
therapeut
potenti
agonist
pulmonari
arteri
hypertens
pah
explor
number
studi
rat
monocrotalineinduc
pah
gene
therapi
prevent
pahmedi
hypertrophi
function
impair
right
moreov
synthet
activ
improv
pulmonari
arteri
endotheli
function
induc
phosphoryl
endotheli
synthas
dephosphoryl
consequ
increas
bioavail
metaanalysi
assess
efficaci
intervent
pah
reveal
synthet
activ
among
potent
although
find
strongli
support
therapeut
potenti
activ
translat
agent
clinic
set
remain
challeng
membranebound
enzym
cleav
solubl
catalyt
activ
form
given
increas
circul
level
might
therapeut
effect
recombin
human
develop
test
anim
model
administr
improv
right
ventricular
function
mice
subject
pressur
attenu
vascular
remodel
mice
bleomycininduc
pulmonari
pilot
studi
evalu
effect
increas
enzymat
activ
intraven
infus
mgkg
mgkg
patient
drug
well
toler
benefici
effect
pulmonari
vascular
resist
cardiac
output
addit
reduc
inflammatori
marker
increas
superoxid
dismutas
level
plasma
nonetheless
proofofconcept
studi
includ
five
patient
separ
studi
administr
also
shown
well
toler
patient
acut
respiratori
distress
safeti
profil
need
assess
clinic
studi
angiotensin
ma
receptor
activ
might
also
protect
role
develop
notabl
howev
angiotensin
consid
good
therapeut
candid
owe
pharmacokinet
limit
angiotensin
rapidli
cleav
peptidas
thu
short
halflif
howev
cell
signal
mechan
effect
mediat
biolog
peptid
thought
persist
despit
short
furthermor
studi
anim
model
shown
administr
angiotensin
includ
cyclodextrin
complex
neuroprotect
effect
improv
muscl
damag
induc
eccentr
cardiac
stabl
cyclic
analogu
angiotensin
moder
reduc
right
ventricular
systol
pressur
rat
model
monocrotalineinduc
pah
signific
chang
observ
medial
wall
thick
pulmonari
optim
protect
potenti
angiotensin
analogu
treatment
pah
compound
potenti
combin
neprilysin
inhibitor
whether
approach
effect
maintain
high
level
angiotensin
requir
investig
activ
attenu
right
ventricular
pulmonari
stimul
protect
mice
sever
lung
injuri
induc
sepsi
acid
wherea
defici
exacerb
hf
mice
subject
acut
myocardi
furthermor
activ
use
agonist
dkcangiotensin
rat
model
chronic
lung
diseas
protect
heart
lung
damag
diminish
inflammatori
respons
attenu
right
ventricular
hypertrophi
well
reduc
vascular
wall
thick
alveolar
septum
agonist
compound
also
shown
inhibit
cardiopulmonari
fibrosi
right
ventricular
remodel
rat
model
monocrotalineinduc
date
one
preclin
studi
assess
effect
angiotensin
adult
rat
pah
treat
angiotensin
show
reduc
right
ventricular
weight
systol
pressur
well
diminish
lung
fibrosi
pulmonari
arteriol
thick
endotheli
damag
compar
untreat
control
effect
depend
activ
ma
receptor
treatment
angiotensin
also
reduc
plasma
level
proinflammatori
marker
tumour
necrosi
factor
tnf
ccchemokin
ligand
also
known
numer
preclin
studi
shown
stimul
synthet
activ
diminazen
acetur
dize
ma
receptor
agonist
human
recombin
reduc
blood
pressur
attenu
cardiovascular
damag
howev
other
studi
found
associ
hypertens
activ
synthet
xnt
reduc
blood
pressur
angiotensin
iiinduc
model
hypertens
plasma
concentr
angiotensin
ii
angiotensin
remain
moreov
antihypertens
effect
drug
observ
mice
neither
xnt
dize
induc
enzymat
activ
rat
mous
find
rais
question
whether
research
continu
focu
drug
unknown
mechan
action
howev
remain
appeal
therapeut
target
treat
hypertens
especi
tissu
express
enzym
higher
therapeut
potenti
dize
altern
treatment
hypertens
pah
shown
previou
experiment
moreov
deoxycorticosteron
acet
doca
hypertens
rat
treat
ma
receptor
agonist
lower
blood
pressur
level
untreat
antihypertroph
effect
part
mediat
inhibit
nadph
oxidas
nadph
oxidas
observ
hypertens
mice
subject
aortic
present
effect
activ
evalu
preclin
studi
rigor
evalu
agent
exert
benefici
effect
need
test
clinic
set
order
identifi
offtarget
potenti
toxic
effect
activ
also
assess
patient
high
blood
pressur
level
angiotensin
iidegrad
activ
monocytederiv
macrophag
vitro
found
similar
cell
healthi
individu
patient
note
activ
significantli
higher
monocytederiv
macrophag
patient
prehypertens
patient
hypertens
suggest
potenti
role
earli
marker
hypertens
find
might
also
indic
physiolog
protect
mechan
hypertens
probabl
rapid
degrad
angiotensin
contrast
correl
found
hypertens
activ
patient
stsegment
elev
myocardi
plasma
level
suggest
vari
depend
although
research
explor
role
cvd
consid
sexrel
differ
activ
level
pregnanc
plasma
level
angiotensin
ii
significantli
elev
wherea
angiotensin
level
significantli
diminish
togeth
might
predispos
pregnant
women
hypertensionrel
furthermor
level
urinari
angiotensin
patient
hypertens
report
invers
proport
blood
pressur
level
impli
crucial
role
peptid
develop
final
angiotensin
also
shown
allevi
obesityinduc
haemodynam
alamandin
heptapeptid
form
catalyt
action
angiotensin
directli
angiotensin
heart
oral
administr
inclus
compound
alamandin
cyclodextrin
reduc
blood
pressur
spontan
hypertens
rat
diminish
myocardi
fibrosi
isoprenalinetr
antihypertens
effect
shown
two
phase
initi
mean
arteri
pressur
left
ventricular
systol
pressur
increas
briefli
manner
follow
reduct
paramet
persist
throughout
rest
infus
period
antihypertens
effect
revers
addit
alamandin
treatment
mitig
vascular
remodel
mice
subject
transvers
aortic
addit
studi
requir
understand
complex
regul
alamandin
cell
signal
cascad
trigger
therapeut
implic
hypertens
cvd
normal
rang
alamandin
level
healthi
individu
patient
hypertens
establish
provid
better
understand
effect
ra
inhibit
alamandin
plasma
concentr
clinic
context
vasodilatori
effect
activ
demonstr
mice
overexpress
mice
lack
show
increas
respons
angiotensin
ii
significantli
elev
blood
pressur
wherea
transgen
overexpress
vascular
smooth
muscl
cell
mice
reduc
angiotensin
iiinduc
antihypertens
effect
agonist
angiotensin
also
obes
rat
reduc
blood
pressur
level
compar
untreat
rat
associ
increas
urinari
sodium
agonist
also
decreas
blood
pressur
level
spontan
hypertens
prevent
endotheli
cell
migrat
mediat
vascular
endotheli
growth
factor
specif
rho
kinas
inhibitor
fasudil
significantli
increas
plasma
level
angiotensin
normotens
hypertens
addit
fasudil
reduc
blood
pressur
level
aortic
rho
kinas
ace
activ
wherea
mrna
protein
level
increas
plasma
aortic
interestingli
anoth
studi
show
increas
ace
angiotensin
ii
level
patient
high
risk
acut
pulmonari
embol
compar
healthi
moreov
rat
model
acut
pulmonari
embol
signal
mediat
imbal
ra
vasoconstrictor
revers
rock
inhibitor
find
highlight
protect
effect
rock
inhibit
exert
set
hypertens
atherosclerosi
patholog
cardiovascular
remodel
studi
ocaranza
colleagu
administr
angiotensin
reduc
blood
pressur
level
hypertens
rat
attenu
myocardi
damag
inhibit
develop
ventricular
hypertrophi
fibrosi
importantli
effect
mediat
ma
receptor
howev
separ
studi
gene
deliveri
angiotensin
adenoassoci
viru
aav
mice
subject
coronari
arteri
ligat
complet
restor
systol
blood
pressur
level
cardiac
output
compar
shamtreat
mice
histolog
analysi
reveal
mild
effect
cardiac
hypertrophi
notabl
ocaranza
colleagu
evalu
angiotensin
administr
compar
latter
studi
examin
effect
peptid
conflict
find
two
studi
suggest
attenu
myocardi
damag
might
transient
sustain
long
term
howev
latter
studi
measur
plasma
level
angiotensin
aavmedi
gene
deliveri
angiotensin
might
produc
therapeut
concentr
peptid
blood
would
suffici
protect
heart
advers
structur
remodel
studi
test
antihypertens
action
angiotensin
strokepron
spontan
hypertens
rat
also
found
evid
protect
studi
use
dose
angiotensin
six
time
lower
use
ocaranza
addit
studi
warrant
explor
antihypertens
antiremodel
effect
angiotensin
administr
implic
plasma
level
peptid
cardioprotect
although
efficaci
angiotensin
administr
explor
clinic
set
patient
acut
respiratori
distress
syndrom
higher
angiotensin
level
plasma
associ
reduc
mortal
wherea
increas
plasma
angiotensin
level
associ
increas
critic
heart
fluid
mutant
mice
impair
contractil
increas
express
hypoxia
marker
increas
circul
level
angiotensin
ii
compar
control
furthermor
mutant
mice
develop
angiotensin
iimedi
dilat
cardiomyopathi
character
increas
marker
oxid
stress
inflamm
patholog
hypertrophi
impair
left
ventricular
interestingli
plasma
level
solubl
form
report
elev
patient
hf
reduc
eject
fraction
suggest
sustain
activ
counterregulatori
ra
hf
might
compensatori
mechan
attenu
cardiovascular
mechan
underli
hf
preserv
eject
fraction
hfpef
remain
poorli
defin
progress
diseas
propos
link
hypertensioninduc
cardiac
given
antihypertens
antiremodel
effect
counterregulatori
ra
describ
thu
far
noncanon
signal
pathway
might
potenti
therapeut
target
treatment
hfpef
angiotensin
ii
infus
wildtyp
mice
result
increas
blood
pressur
level
myocardi
hypertrophi
fibrosi
diastol
dysfunct
effect
exacerb
convers
treatment
angiotensin
iiinfus
wildtyp
mice
reduc
angiotensin
iiinduc
superoxid
product
blunt
cardiac
hypertroph
respons
highlight
possibl
protect
role
enzym
compon
noncanon
ra
pathway
also
involv
hf
mice
defici
alamandin
receptor
mrgd
left
ventricular
remodel
sever
dysfunct
present
pronounc
dilat
furthermor
infus
agonist
day
rat
hf
induc
coronari
arteri
ligat
led
reduct
noradrenalin
excret
well
decreas
renal
sympathet
nerv
addit
administr
increas
baroreflex
sensit
suggest
protect
role
drug
set
hf
collect
find
support
role
variou
compon
counterregulatori
ra
hf
potenti
biomark
therapeut
target
addit
clinic
studi
need
determin
level
angiotensin
angiotensin
patient
hf
role
noncanon
ra
signal
develop
myocardi
infarct
describ
mrna
level
elev
set
myocardi
wherea
loss
exacerb
cardiac
token
overexpress
shown
allevi
myocardi
damag
induc
furthermor
administr
angiotensin
ad
oligosaccharid
hydroxypropyl
rat
myocardi
infarct
improv
cardiac
function
reduc
infarct
size
likewis
transgen
rat
overexpress
fusion
protein
lead
select
increas
angiotensin
level
less
suscept
reperfusioninduc
arrhythmia
isoproterenolinduc
hypertrophi
wildtyp
cardioprotect
role
prevent
postischaem
cardiac
remodel
mice
lack
aggrav
myocardi
infarctioninduc
hf
reduc
surviv
compar
shamtreat
correspondingli
transgen
mice
overexpress
show
improv
left
ventricular
function
myocardi
similar
result
observ
rat
cardiacspecif
overexpress
administr
agonist
rat
subject
coronari
arteri
ligat
significantli
improv
recoveri
left
ventricular
function
reduc
cardiac
remodel
myocardi
deliveri
angiotensin
aav
vector
mice
induct
myocardi
infarct
result
reduct
sudden
cardiac
death
improv
left
ventricular
function
compar
control
importantli
angiotensin
posit
inotrop
effect
achiev
increas
calciumtransi
amplitud
contractil
protein
kinas
adepend
use
ex
vivo
approach
isol
rat
heart
subject
global
ischaemia
reperfus
mendozatorr
colleagu
show
angiotensin
infus
also
reduc
infarct
size
apoptot
necrot
cell
death
improv
left
ventricular
function
aktdepend
togeth
data
suggest
angiotensin
angiotensin
might
valuabl
pharmacolog
tool
treatment
myocardi
infarct
given
acut
longterm
cardioprotect
effect
inflammatori
process
central
develop
progress
cvd
atherosclerosi
hypertens
myocardi
infarct
link
inflamm
ra
previous
observ
cell
endogen
ra
regul
cell
function
nadph
oxidas
activ
superoxid
natur
killer
cell
also
shown
express
renin
angiotensinogen
ace
line
observ
proinflammatori
state
thought
upregul
ra
signal
set
interestingli
human
monocyt
also
express
ace
produc
angiotensin
angiotensin
taken
togeth
data
suggest
immun
system
might
also
involv
regul
noncanon
ra
activ
ma
receptor
shown
promot
antiinflammatori
mice
lack
receptor
exacerb
inflammatori
reaction
treatment
lipopolysaccharid
compar
wildtyp
therefor
ma
receptor
activ
might
valuabl
therapeut
target
counteract
proinflammatori
process
promot
develop
progress
inde
ma
receptor
agonist
inhibit
atherogenesi
moreov
longterm
angiotensin
treatment
confer
vasoprotect
improv
endotheli
function
atheroprotect
reduc
lesion
progress
consist
observ
angiotensin
activ
signal
pathway
critic
resolut
inflammatori
process
involv
addit
ma
receptor
signal
also
associ
regul
inflamm
agonist
dosedepend
attenu
lipopolysaccharideinduc
tnf
product
increas
product
antiinflammatori
cytokin
consist
observ
separ
studi
show
administr
prehypertens
obes
zucker
rat
reduc
plasma
level
tnf
wherea
coadministr
antagonist
decreas
level
furthermor
wistar
rat
subject
left
coronari
arteri
ligat
treatment
reduc
product
proinflammatori
cytokin
manner
improv
systol
diastol
ventricular
function
reduc
scar
angiotensin
administr
also
shown
reduc
cardiac
renal
inflamm
model
hypertens
rat
effect
independ
despit
substanti
amount
evid
suggest
counterregulatori
role
noncanon
ra
protect
deleteri
action
dysregul
classic
ra
complex
relationship
two
system
remain
fulli
elucid
exampl
elev
patient
depress
patient
discrep
suggest
compon
counterregulatori
ra
upregul
downregul
depend
stage
sever
type
cvd
moreov
conflict
find
reinforc
lack
knowledg
physiolog
pathophysiolog
mechan
involv
noncanon
ra
regul
instanc
elev
level
solubl
might
repres
compensatori
mechan
respons
hf
might
also
result
increas
cleavag
membran
disintegrin
metalloproteinas
domaincontain
protein
known
upregul
addit
ra
peptid
also
modul
pharmacolog
treatment
regard
patient
chronic
hf
treat
ace
inhibitor
elev
plasma
level
angiotensin
reduc
plasma
level
angiotensin
ii
wherea
patient
acut
hf
treat
angiotensin
ii
receptor
antagonist
decreas
plasma
level
angiotensin
increas
plasma
level
angiotensin
furthermor
addit
plasma
sampl
patient
hf
induc
convers
angiotensin
angiotensin
ii
angiotensin
angiotensin
addit
aforement
challeng
interpret
data
noncanon
ra
measur
angiotensin
angiotensin
alamandin
clinic
context
pose
mani
challeng
separ
peptid
biolog
sampl
difficult
given
similar
molecular
structur
angiotensin
two
amino
acid
shorter
angiotensin
wherea
angiotensin
alamandin
differ
ntermin
amino
fig
therefor
identif
peptid
requir
use
highprecis
approach
highperform
liquid
chromatographi
mass
spectrometri
box
furthermor
one
fundament
problem
associ
use
peptid
clinic
context
short
plasma
halflif
owe
rapid
enzymat
degrad
numer
ongo
clinic
trial
assess
effect
angiotensin
cvd
angiotensin
administ
via
subcutan
intraven
howev
cycliz
angiotensin
analogu
describ
increas
halflif
improv
resist
enzymat
degrad
superior
function
activ
compar
natur
angiotensin
similar
chemic
modif
angiotensin
peptid
might
also
prolong
halflif
peptid
howev
nonpeptid
agonist
halflif
h
also
induc
agonist
high
select
receptor
well
howev
although
result
date
promis
angiotensin
still
requir
extens
safeti
efficaci
assess
potenti
endogen
agonist
oral
bioavail
agonist
also
report
modul
epigenet
mechan
associ
pathophysiolog
diabet
rais
possibl
unwant
offtarget
effect
use
treat
cvd
studi
compar
effect
angiotensin
use
establish
potenti
differ
two
agent
challeng
hinder
clinic
translat
counterregulatori
ra
compon
treatment
cvd
overcom
therapeut
agent
might
use
complement
tradit
pharmacolog
treatment
complementari
drug
necessari
even
goldstandard
drug
hypertens
associ
issu
suboptim
drug
efficaci
adher
patient
hypertens
especi
comorbid
requir
two
drug
manag
blood
pressur
furthermor
mani
patient
requir
two
dose
suggest
separ
use
ace
inhibitor
angiotensin
ii
receptor
antagonist
alway
effect
use
one
drug
need
multipl
dose
per
day
increas
incid
advers
event
result
loss
addit
longitudin
studi
evalu
dose
histori
patient
take
antihypertens
drug
found
nearli
half
patient
cohort
discontinu
result
poorli
control
combin
counterregulatori
ra
peptid
current
goldstandard
antihypertens
drug
one
pill
might
overcom
need
patient
hypertens
comorbid
receiv
one
drug
multipl
dosag
drug
per
day
counterregulatori
ra
peptid
angiotensin
alamandin
angiotensin
found
effect
reduc
blood
pressur
attenu
cardiovascular
remodel
preclin
effect
might
achiev
fewer
advers
reaction
patient
hypertens
compar
current
antihypertens
therapi
turn
might
improv
treatment
adher
combin
angiotensin
angiotensinreceptor
blocker
losartan
might
increas
extend
blood
pressurelow
importantli
antiatherosclerot
effect
dual
angiotensin
losartan
therapi
pharmacolog
synergi
current
goldstandard
treatment
cvd
counterregulatori
ra
peptid
might
decreas
dosag
requir
achiev
efficaci
therebi
reduc
advers
effect
howev
although
endogen
origin
counterregulatori
ra
compon
suggest
safe
pharmacolog
profil
current
lack
robust
evid
patient
mean
hypothesi
remain
test
evid
support
protect
role
counterregulatori
ra
cvd
robust
incomplet
addit
methodolog
pitfal
must
overcom
futur
research
also
conduct
larg
anim
high
translat
valu
confirm
data
studi
carri
vitro
smallanim
model
role
ra
peptid
angiotensin
iii
angiotensin
iv
cardiovascular
system
warrant
investig
furthermor
assess
classic
counterregulatori
ra
peptid
routin
clinic
evalu
patient
cvd
consid
although
develop
practic
afford
accur
method
assess
level
requir
achiev
reliabl
readout
balanc
imbal
level
peptid
plasma
urin
might
use
marker
cvd
moreov
thorough
evalu
counterregulatori
ra
profil
patient
might
bring
current
therapeut
approach
step
closer
goal
precis
medicin
allow
tailor
treatment
plan
patient
optim
drug
efficaci
adher
